---
document_datetime: 2023-09-21 20:34:14
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/portrazza-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: portrazza-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5334645
conversion_datetime: 2025-12-19 21:17:52.930207
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Portrazza

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                             | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                               |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10471 /201605  | Periodic Safety Update EU Single assessment - NECITUMUMAB                                                                                                                                                                                                                                                                         | 01/12/2016                                  | n/a                                         |                                  | PRAC Recommendation - maintenance                                                                                                                                                                     |
| II/0002              | Submission of study I4X-MC-JFCL, investigating necitumumab in combination with paclitaxel and carboplatin chemotherapy versus paclitaxel and carboplatin chemotherapy alone as the first line therapy in patients with Stage IV metastatic squamous non-small cell lung cancer (NSCLC). This variation leads to amendments of the | 10/11/2016                                  |                                             | SmPC, Labelling and PL           | Assessment of the data provided in the context of this variation led to amendments of the SmPC to reflect the findings. The following text was added to sections 4.4 and 5.1. Section 4.4: Infections |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet).

The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

<!-- image -->

<div style=\"page-break-after: always\"></div>

IB/0006

Product Information: sections 4.4 and 5.1 of the SmPC were updated to reflect the findings of the study submitted. The update is being reflected in the PL.

C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority

B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS

In a phase 2 clinical trial investigating necitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone as the firstÂ¬ line therapy in patients with Stage IV metastatic squamous NSCLC, an increased rate of infections was observed early after start of treatment, which led to subsequent infectious complications such as pneumonia and/or sepsis.  A similar observation was made in a clinical trial investigating necitumumab in combination with pemetrexed and cisplatin versus pemetrexed and cisplatin alone as the first line therapy in patients with advanced non squamous NSCLC. Special attention should be given to patients with clinical evidence of concomitant infectious conditions including early signs of active infections.  Treatment of any infection should be initiated according to local standards.

In a phase 2 clinical trial investigating necitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone (106 versus 55 patients, 2:1 randomisation) as the first line therapy in patients with Stage IV metastatic squamous NSCLC, a higher rate of death, including death due to infection, was observed for the necitumumab plus paclitaxel/carboplatin arm during the first 4 months (see also section 4.4), with a later trend towards improved survival after 4 months.  The overall survival hazard ratio [HR] was 0.83 [0.55, 1.52]. The PL was amended accordingly.

Section 5.1: 25/10/2016 n/a Medicinal product no longer authorised

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0004/G   | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                            | 18/07/2016   | n/a    | authorised             |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------|------------------------|
| IB/0003/G   | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch product | 16/06/2016   | n/a no | longer                 |
| IAIN/0001   | control/testing takes place A.1 - Administrative change - Change in the name and/or address of the MAH Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 22/03/2016   |        | SmPC, Labelling and PL |